Table 1.

Cardiotoxicity risk assessment

Risk of cardiotoxicity related to cancer treatment	Criteria for high CV risk of developing cardiotoxicity
High risk  Anthracyclines, cyclophosphamide, ifosfamide, trastuzumab, and clofarabine Intermediate risk  Docetaxel, pertuzumab, sunitinib, and sorafenib	History of:  Cardiomyopathy or heart failure  Ischemic heart disease  Arrhythmias under treatment  QTc >500 ms
Low risk  Bevacizumab, dasatinib, imatinib, lapatinib, etoposide, rituximab, and thalidomide	HT Diabetes Previous use of anthracyclines Mediastinal radiotherapy Female gender <15 years or >65 years

CV cardiovascular, HT hypertension, QTc corrected QT interval